Filter Results:
(1,304)
Show Results For
- All HBS Web
(1,304)
- People (4)
- News (228)
- Research (903)
- Events (4)
- Multimedia (7)
- Faculty Publications (498)
Show Results For
- All HBS Web
(1,304)
- People (4)
- News (228)
- Research (903)
- Events (4)
- Multimedia (7)
- Faculty Publications (498)
- August 2003 (Revised January 2013)
- Case
Multinational Corporations in Apartheid-era South Africa: The Issue of Reparations
By: Geoffrey Jones and Cate Reavis
Considers the lawsuits filed on behalf of victims of apartheid against multinationals who operated in South Africa prior to 1994. Reviews the debates about divestment from and sanctions against South Africa from the 1950s. Includes case studies of companies that... View Details
Keywords: Ethics; Multinational Firms and Management; Government Legislation; Lawsuits and Litigation; Business and Government Relations; Prejudice and Bias; South Africa
Jones, Geoffrey, and Cate Reavis. "Multinational Corporations in Apartheid-era South Africa: The Issue of Reparations." Harvard Business School Case 804-027, August 2003. (Revised January 2013.)
- August 2018 (Revised February 2019)
- Case
Alvogen: Scaling Entrepreneurship
By: Daniel Isenberg, William R. Kerr and Alexis Brownell
Keywords: Pharmaceutical Companies; Scaling; Generic Drugs; Entrepreneurship; Leadership; Pharmaceutical Industry; Asia; Europe; United States; Iceland
Isenberg, Daniel, William R. Kerr, and Alexis Brownell. "Alvogen: Scaling Entrepreneurship." Harvard Business School Case 819-038, August 2018. (Revised February 2019.)
- June 2017
- Supplement
Transformation at Eli Lilly & Co. (B)
By: William R. Kerr and Alexis Brownell
Keywords: Eli Lilly; Pharmaceutical Companies; Restructuring; Organizational Change and Adaptation; Pharmaceutical Industry; Indiana; Indianapolis
Kerr, William R., and Alexis Brownell. "Transformation at Eli Lilly & Co. (B)." Harvard Business School Supplement 817-136, June 2017.
- 16 Jul 2012
- Working Paper Summaries
Selection, Reallocation, and Spillover: Identifying the Sources of Gains from Multinational Production
Keywords: by Laura Alfaro & Maggie X. Chen
- November 2016
- Supplement
Alnylam Pharmaceuticals: Building Value from the IP Estate (B)
By: Vicki Sato, Willy Shih and Matt Higgins
The leader of a pioneering biotech company in the siRNA space weighs his options for scaling production capacity in advance of an anticipated commercial launch. Operational complexity and relative merits of in-house manufacturing versus a contractor model are... View Details
Keywords: Pharmaceutical Companies; Pharmaceutical Industry; Biotech; Biotechnology; Operational Complexity; Strategy; Manufacturing; Production; Strategic Planning; Intellectual Property; Biotechnology Industry; United States
Sato, Vicki, Willy Shih, and Matt Higgins. "Alnylam Pharmaceuticals: Building Value from the IP Estate (B)." Harvard Business School Supplement 617-022, November 2016.
- 2021
- Chapter
Multinationals' Need for State Protection: The Creation of the Swiss Investment Risk Guarantee in the 1960s
By: Sabine Pitteloud
This chapter focuses on the role of Industrie-Holding, the Federation of Swiss Industrial Multinational Companies, in the introduction of an investment risk guarantee during the 1960s. The chapter therefore contributes to a) the growing body of literature on how... View Details
Keywords: Investments; Multinational Companies; Political Risk; Business ＆ Government Relations; Investment; Multinational Firms and Management; Risk and Uncertainty; Business and Government Relations; Switzerland
Pitteloud, Sabine. "Multinationals' Need for State Protection: The Creation of the Swiss Investment Risk Guarantee in the 1960s." In Security and Insecurity in Business History: Case Studies in the Perception and Negotiation of Threats, edited by Mark Jakob, Nina Kleinöder, and Christian Kleinschmidt, 111–134. Baden-Baden: Nomos Verlagsgesellschaft, 2021.
- November 2024
- Teaching Note
Martine Rothblatt and United Therapeutics: A Series of Implausible Dreams
By: Debora L. Spar and Julia M. Comeau
Teaching Note for HBS Case No. 323-039. In 1990, satellite expert and Sirius XM founder Martine Rothblatt was determined to save the life of her seven-year-old daughter, Jenesis, who was diagnosed with a terminal illness called Pulmonary Arterial Hypertension (PAH). At... View Details
Keywords: Pharmaceutical Companies; Technological And Scientific Innovation; Organ Donation; Health Care and Treatment; Health Disorders; Innovation and Invention; Growth and Development Strategy; Product Development; Pharmaceutical Industry; Pharmaceutical Industry; United States; District of Columbia
- November 2022 (Revised April 2024)
- Case
Martine Rothblatt and United Therapeutics: A Series of Implausible Dreams
By: Debora L. Spar and Julia M. Comeau
In 1990, satellite expert and Sirius XM founder Martine Rothblatt was determined to save the life of her seven-year-old daughter, Jenesis, who was diagnosed with a terminal illness called Pulmonary Arterial Hypertension (PAH). At the time, there was little medication... View Details
Keywords: Pharmaceutical Companies; Technological And Scientific Innovation; Organ Donation; Health Care and Treatment; Health Disorders; Innovation and Invention; Pharmaceutical Industry; Pharmaceutical Industry; United States; District of Columbia
Spar, Debora L., and Julia M. Comeau. "Martine Rothblatt and United Therapeutics: A Series of Implausible Dreams." Harvard Business School Case 323-039, November 2022. (Revised April 2024.)
- September 2020 (Revised January 2021)
- Case
Catalys Pacific
In 2019, BT Slingsby founds Catalys Pacific, the first biotech “venture creation” fund in Tokyo. After convincing some of the biggest Japanese pharmaceutical firms to invest, BT hopes the fund can make a big splash and transform biotechnology innovation in Japan. After... View Details
Keywords: Pharmaceutical Companies; Biotech; Health Care; Entrepreneur; Innovation; International Business; Entrepreneurial Finance; Entrepreneurship; Finance; Innovation Strategy; Venture Capital; Strategy; Cross-Cultural and Cross-Border Issues; Pharmaceutical Industry; Pharmaceutical Industry; Tokyo
Krieger, Joshua Lev. "Catalys Pacific." Harvard Business School Case 821-035, September 2020. (Revised January 2021.)
- February 2022 (Revised November 2022)
- Case
Nuritas
By: Mitchell Weiss, Satish Tadikonda, Vincent Dessain and Emer Moloney
Nora Khaldi had built a technology “to unlock the power of nature” in the service of extending human lifespan and improving health, and now in April 2020 was debating telling her Board of Directors she wanted to put on ice some of her discoveries. Nuritas, the company... View Details
Keywords: Cash Burn; Cash Flow Analysis; Pharmaceutical Companies; Founder; Artificial Intelligence; AI; Entrepreneurship; Health Testing and Trials; Health Care and Treatment; Decision Making; Market Entry and Exit; AI and Machine Learning; Pharmaceutical Industry
Weiss, Mitchell, Satish Tadikonda, Vincent Dessain, and Emer Moloney. "Nuritas." Harvard Business School Case 822-080, February 2022. (Revised November 2022.)
- 29 Jan 1994
- Lecture
Multinational Governance in Global Companies: The Conflict Between Companies that Have Become Global and Boards that are Still National
By: W. Carl Kester
Kester, W. Carl. "Multinational Governance in Global Companies: The Conflict Between Companies that Have Become Global and Boards that are Still National." Lecture at the World Economic Forum Annual Meeting, Davos, Switzerland, January 29, 1994. (Moderator for the panel discussion.)
- 2009
- Working Paper
Securing Jobs or the New Protectionism?: Taxing the Overseas Activities of Multinational Firms
By: Mihir A. Desai
Tax policy toward American multinational firms would appear to be approaching a crossroads. The presumed linkages between domestic employment conditions and the growth of foreign operations by American firms have led to calls for increased taxation on foreign... View Details
Keywords: Multinational Firms and Management; Policy; Taxation; Job Cuts and Outsourcing; United States
Desai, Mihir A. "Securing Jobs or the New Protectionism?: Taxing the Overseas Activities of Multinational Firms." Harvard Business School Working Paper, No. 09-107, March 2009.
- 06 Sep 2022
- Research & Ideas
Curbing an Unlikely Culprit of Rising Drug Prices: Pharmaceutical Donations
counterintuitive driver: the fact that in the US, pharmaceutical companies subsidize the purchase of their drugs. Medicare, the government insurer for elderly or disabled people in the US, encourages... View Details
- 2001
- Book
Foreign Multinationals in the United States: Management and Performance
By: Geoffrey Jones and Lina Galvez-Munoz
In this volume, leading scholars in international business and business history examine the investments and performance of British, Canadian, French, German, Spanish and Japanese firms in the United States over time. They explore why so many foreign firms experience... View Details
Keywords: Investment; Multinational Firms and Management; Books; Management; Performance; Perspective; United States
Jones, Geoffrey, and Lina Galvez-Munoz, eds. Foreign Multinationals in the United States: Management and Performance. London: Routledge, 2001.
- 2022
- Chapter
Crises and International Business
By: Geoffrey Jones
This chapter uses the intellectual journey of the author to suggest that crises have been the norm rather than the exception in the history of international business. Over the last 100 years world wars, regional conflicts, the Great Depression, and decolonization are... View Details
Keywords: Crisis; Multinational Companies; International Business; Emerging Market; Business History; Multinational Firms and Management; System Shocks; War; Emerging Markets; Crisis Management
Jones, Geoffrey. "Crises and International Business." Chap. 2 in International Business in Times of Crisis. Vol. 16, edited by Rob van Tulder, Alain Verbeke, Lucia Piscitello, and Jonas Puck, 27–32. Progress in International Business Research. Bingley, UK: Emerald Publishing Limited, 2022.
How Companies in Emerging Markets Break Out
In this interview with Harvard Business Review, Krishna Palepu explains how multinationals and local companies can win in emerging markets.
View Details
View Details
- August 2024 (Revised February 2025)
- Case
Novo Nordisk Foundation
By: Debora L. Spar and Julia M. Comeau
In 2024, Novo Nordisk A/S was one of the most profitable firms in the world, thanks largely to just two GLP-1-based drugs, Ozempic and Wegovy. Unusually, this incredibly profitable firm was controlled not by individual private shareholders, but by a non-profit... View Details
Keywords: Pharmaceutical Companies; Diabetes; Obesity; Foundation; Non-profit Management; Profit; Corporate Governance; Business or Company Management; Corporate Social Responsibility and Impact; Expansion; Philanthropy and Charitable Giving; Nonprofit Organizations; Pharmaceutical Industry; Denmark; Europe
Spar, Debora L., and Julia M. Comeau. "Novo Nordisk Foundation." Harvard Business School Case 325-031, August 2024. (Revised February 2025.)
- Spring 2014
- Article
Attracting Long-Term Investors Through Integrated Thinking and Reporting: A Clinical Study of a Biopharmaceutical Company
By: Andrew Knauer and George Serafeim
Faced with a large percentage of investors that chase short-term returns, companies could benefit by attracting investors with longer-term horizons and incentives that are more consistent with the long-term strategy of the company. The managers of most companies take... View Details
Keywords: Investing; Asset Management; Long-term Investing; Short-termism; Sustainability; Integrated Reporting; Leadership & Corporate Accountability; Pharmaceuticals; Leadership; Integrated Corporate Reporting; Investment; Business and Stakeholder Relations; Corporate Finance; Pharmaceutical Industry; Pharmaceutical Industry
Knauer, Andrew, and George Serafeim. "Attracting Long-Term Investors Through Integrated Thinking and Reporting: A Clinical Study of a Biopharmaceutical Company." Journal of Applied Corporate Finance 26, no. 2 (Spring 2014): 57–64.